1 JANUARY – 30 SEPTEMBER 2022
Growth in a changing market
NET SALES
EBITA
EARNINGS GROWTH
EBITA R12 MONTHS
P/WC
Long-term positive trend in demand
AddLife's sales in the third quarter increased by 14 percent year-on-year. Organic growth excluding COVID-19 was 2 percent. As expected, COVID-related sales in the Labtech business area continued to decline, but organic growth, excluding COVID-19, was 5 percent. The decrease in COVID-related sales has been fully offset by revenue from acquired businesses in the Medtech business area.
A leading player in Life Science
AddLife is a listed Swedish Medtech company active on the European market. AddLife owns and acquires companies in niche segments with offerings aimed primarily at the healthcare sector, from research to medical care. The subsidiaries are divided into two business areas. Labtech offers products, solutions and a wide range of diagnostic services, biomedical research and laboratory analysis. Medtech offers products, solutions and services in medical technology and home care.
Acquisitions during the interim period
During the interim period, five acquisitions were completed. These acquisitions are estimated to contribute with annual net sales of approximately SEK 850m and approximately 350 employees.
